Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502788 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)
A Phase 2 study, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00502788 is a Phase 2 study that has completed, run by Carelon Research. The registered enrollment target is 21 participants.
The verdict
NCT00502788, a Phase 2 study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Hepatitis C is one of the most common causes of long-term liver disease in the United States. Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C infection. The purpose of this study is to evaluate the safety of these two medications in adults with hepatitis C and thalassemia, a type of blood disorder.
Interventions
- DRUG Ribavirin
- DRUG Peginterferon Alfa-2a and Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00502788
The ClinicalTrials.gov registry entry for NCT00502788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ribavirin is the first listed.
NCT00502788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00502788 about?
NCT00502788 is a clinical study titled "Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)". Hepatitis C is one of the most common causes of long-term liver disease in the United States. Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C infection. The purpose of this study is to evaluate the safety of these two medications in adults with hepatitis C ...
What is the current status of trial NCT00502788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2003-05. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00502788?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon Alfa-2a and Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00502788?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.